THE DIFFERENCE IS

PUTTING PRECISION
TO WORK


BEFORE. DURING. AND AFTER.

BD MAX™ is your partner in this storm.

Like you, we understand your responsibility to protect patients and communities through these challenging times. It's never been more important to have the support and experience of a trusted partner.

BD is your trusted partner supporting you with molecular diagnostics.

The COVID-19 pandemic continues to surge with new cases and hospitalizations. Flu season presents an additional challenge for clinicians in differentiation between these two highly transmissible respiratory viruses. The BD MAX™ System provides molecular testing for the simultaneous detection and differentiation of SARS-CoV-2 and influenza A and B*.

Discovery. Diagnostics. Delivery.

Can be accessed on our Customer Learning Portal. The e-learning courses offer detailed and solution focused training to help better understand how to solve for common scenarios.

Mother and child

SARS-CoV-2 Variants
New variants of the SARS-CoV-2 virus have one or more differentiating mutations than the predominant strains already circulating globallyi. These variants are reported in the GISAID genome sequencing database (Global Influenza Surveillance & Response System)ii. WHO and CDC have identified several of these variants as Variants of Concern potentially impacting diagnostics, patient management or risk of disease transmission.

Completed in-silico analysis indicates that the below Variants of Concern have no impact on the BD SARS-CoV-2 Reagents for BD MAX™ System** and BD SARS-CoV-2/Flu for BD MAX™ System*.

WHO classification Associated location (initial/discovery)
 Other names
Alpha
 England, United Kingdom
VOC-20DEC-01, 20B/501Y.V1
Beta
 South Africa
VOC-20DEC-02, 501.V2, 20C/501Y.V2
Delta
 India

Epsilon
 California
CAL.20C
Gamma
 Brazil/Japan
VOC-21JAN-02, 20J/501Y.V3
Iota
 United States

Kappa
 India

Lambda
 Peru
Mu
 Colombia
Omicron (BA.1)
 South Africa
 B.1.1.529
Omicron (BA.2)
 South Africa


We will continue to monitor and update you should there be additional Variants of Concern reported in the US.

† Last BD review of GISAID database, June 24, 2021

For additional questions please contact the BD Medical Information Team at 1-800-555-7422, extension 6 or [email protected]

BD MAX SARS-CoV-2



SARS-CoV-2 testing**
You can’t identify this virus without a reliable test, but the normal development process can take years. We compressed that process from years to weeks to make sure you had what you needed for this fight. We offer multiple assays:

  • BioGX SARS-CoV-2 Reagents**

  • BD SARS-CoV-2 Reagents**



BD manufacturing






Increased capacity
We are building out manufacturing capacity to expand to nearly double the tests made per week, so you’ll have the supplies you need not only for SARS-CoV-2** but for your other IVD assays.


Experts from around the globe describe the intersection between patient and healthcare worker safety, focusing on techniques to improve both occupational and public health.

Webinar Objectives:

  • Describe the current global impact of bloodborne disease
  • Describe occupational exposure incidents for needlesticks and sharps injuries
  • Define safety as a function of focus for both patient and health worker, to reduce overall bloodborne disease
  • Provide guidance on the importance of prevention programs including use of safer medical devices, immunization/vaccination programs, and safe clinical practices
  • Illustrate an effective pathway for reporting exposure incidents and injuries
  • Define processes for post-exposure medical treatment and prophylaxis
  • Share global experiences from key stakeholders responsible for sharps safety and public health programs around the world

Save Your Seat


Product training, education and clinical resources


Stability. Expertise. Integrity.

What you look for in a partner today will be just as relevant tomorrow

It will, of course, end. Or at least, diminish. Things will reset to a new normal. Bacterial vaginosis, Salmonella, Clostridioides difficile, and Staphylococcus aureus won’t be going away. And when the dust clears, you want to be standing with a partner you can rely on when things were tough.

We were with you before this all started. We are here for you now. And we will be there when it’s over, with more innovative ways to improve molecular diagnostics.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

SARS-CoV-2 testing**
You can’t identify this virus without a reliable test, but the normal development process can take years. We compressed that process from years to weeks to make sure you had what you needed for this fight. We offer multiple assays:

  • BioGX SARS-CoV-2 Reagents**
  • BD SARS-CoV-2 Reagents**

Watch “COVID-19 PCR molecular technology” to see how we developed the test in record time.

Learn more about BD’s response plan to COVID-19 or Watch the in-service video.


Placeholder

Mobilized workforce
While there are supply shortages throughout the industry in these challenging times, we are working around the clock and around the world, increasing our workforce and production, to provide you more supply of instruments and tests.


Placeholder

Increased capacity
We are building out manufacturing capacity to expand to nearly double the tests made per week, so you’ll have the supplies you need not only for SARS-CoV-2* but for your other IVD assays.


The COVID-19 pandemic continues to surge with new cases and hospitalizations. Flu season presents an additional challenge for clinicians in differentiation between these two highly transmissible respiratory viruses. The BD MAX™ System provides molecular testing for the simultaneous detection and differentiation of SARS-CoV-2 and influenza A and B*.

Video title here

Play

Ibus exped et ape

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Ibus exped et ape

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Ibus exped et ape

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Ibus exped et ape

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

How can we help you through this?

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

BD manufacturing

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Store Tab

360° rotation knob is effectively sized, contoured and located to enable easy instrument rotation.

360° rotation knob is effectively sized

360° rotation knob is effectively sized

360° rotation knob is effectively sized

More product details

Store Tab

360° rotation knob is effectively sized, contoured and located to enable easy instrument rotation.

360° rotation knob is effectively sized

360° rotation knob is effectively sized

360° rotation knob is effectively sized

More product details

Efficiency

Labs must juggle competing priorities of increased testing volume while managing costs—all in the midst of a workforce shortage of laboratory professionals.1

The BD MAX™ System can provide results in 90 minutes to 3 hours, with less than 1.5-minute hands-on time per specimen and 15-minutes hands-on time per run2. Individual assay times can vary.

Download brochure >>

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>


These days, it’s not just patients being tested

The global pandemic has put enormous strain on every facet of society. But its impact on the diagnostic testing community has been even greater. There’s more than one front line, with you, the laboratorians and managers who have been risking your health to meet the huge demand for test results are the unsung heroes of this time.

At BD, we’re committed to helping you through this crisis.

E-learning courses

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

User group webcasts

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Let's have a conversation

BD SARS-CoV-2 Reagents for BD MAX™ System: In-service training video
BD MAX™ System In-service training video
Package insert
Reimbursement support
E-learning courses
User group webcasts

Let's have a conversation

Let's have a conversation

REFERENCES

1. American Society for Clinical Laboratory Science, Addressing the Clinical Laboratory Workforce Shortage, accessed November 24, 2020, http://www.ascls.org/images/publications/Clinical_Laboratory_Workforce_FINAL_20180824.pdf
2. Felder RA et al. J Lab Autom. 2014;19(5):468-473. 4. Hirvonen JJ et al. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005-1009.

i Centers for Disease Control. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.htm
ii https://www.gisaid.org/hcov19-variants/
† BD MAX™ Assay package inserts. https://www.eifu.online/BDX?prefix=bdx

*BD SARS-CoV-2/Flu for BD MAX™ System:
• This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
• This product has been authorized only for the detection of nucleic acid of SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens; and
• The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

**BD SARS-CoV-2 Reagents for BD MAX™ System and BioGX SARS-CoV-2 Reagents for BD MAX™ System:
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection of nucleic acid of SARS-CoV-2, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner. .


BD Veritor™ System for Rapid Detection of SARS-CoV-2:
• This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
• This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner
• Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.

Contact us | Unsubscribe | My profile

© BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.

Privacy Policy | Terms of Use